Golexanolone

Golexanolone
Clinical data
Other names	GR-3027; 3α-Ethynyl-3β-hydroxyandrostan-17E-one oxime
Identifiers
	IUPAC name (3S,5S,8R,9S,10S,13S,14S,17E)-3-Ethynyl-17-hydroxyimino-10,13-dimethyl-2,4,5,6,7,8,9,11,12,14,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol;
CAS Number	2089238-18-4;
PubChem CID	132190533;
ChemSpider	76826990;
UNII	9C48F08TP2;
Chemical and physical data
Formula	C21H31NO2
Molar mass	329.484 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@]12CC[C@](C[C@@H]1CC[C@@H]3[C@@H]2CC[C@]\4([C@H]3CC/C4=N\O)C)(C#C)O;
	InChI InChI=1S/C21H31NO2/c1-4-21(23)12-11-19(2)14(13-21)5-6-15-16-7-8-18(22-24)20(16,3)10-9-17(15)19/h1,14-17,23-24H,5-13H2,2-3H3/b22-18+/t14-,15-,16-,17-,19-,20-,21-/m0/s1; Key:FFIBGVYTWNPLPN-BZLGYYABSA-N;

Golexanolone, also known by the developmental code name GR-3027, is a neurosteroid medication which is under development for the treatment of hypersomnia and hepatic encephalopathy.^[1]^[2]^[3]^[4] It acts as a negative allosteric modulator of the GABA_A receptor.^[1]^[2] The medication selectively antagonizes the stimulatory actions of inhibitory neurosteroids like allopregnanolone and tetrahydrodeoxycorticosterone (THDOC) at the GABA_A receptor, while not affecting the activation of the GABA_A receptor by γ-aminobutyric acid (GABA).^[2]